NiKang Therapeutics, Inc.
5 clinical trials · Sponsor
◉ Watch NiKang Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors (NCT07029399) | NiKang Therapeutics, Inc. | 2025-03-25 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors (NCT06586957) | NiKang Therapeutics, Inc. | 2024-09-19 |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (NCT05935748) | NiKang Therapeutics, Inc. | 2023-07-28 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
Track NiKang Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.